BioNTech SE

Youtube Subscribe

Open: 89.7 Close: 90.94 Change: 1.24

Can you guess what an AI found about BioNTech SE Company Inc Stock.

The game is changing. There is a new strategy to evaluate BioNTech SE fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, security, SE, March, action, lawsuit, shareholder, …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

Shareholders of BioNTech SE (BNTX) should contact Levi & Korsinksky about pending Class Action Suit seeking to learn about a potential recovery under the federal securities laws. Shareholders are urged to learn. about a. potential recovery. Shareholders share price for BNTx is 62% below its historic median score of 50 and infers higher risk.

Today's News

Shareholders of BioNTech SE (BNTX) should contact Levi & Korsinsky about pending Class Action Suit seeking to learn about a potential recovery under the federal securities laws. Investor alert: potential recovery for biontech se (bntx) investors. Levi & Korsinsky, LLP notifies investors in BioNTech SE (BioNTech or the Company) (NASDAQ: BNTX) of a class action securities lawsuit. Levi &. Korsinksky, LLP is seeking to learn about a potential recovery under the federal securities laws. Shareholders of BioNTech SE (NASDAQ:BNTX) are urged to learn about a potential recovery under the federal securities laws. Rosen Law Firm reminds purchasers of securities between March 30, 2022 and October 13, 2... biontech se adr rises friday, outperforms market. On March 27, 2023, during pre-market hours, BioNTech issued a press release announcing its fourth quarter and full year 2022 financial results. Following this news, Biontechs ADS price fell $4.60 per ADS, or 3.59%, to close at $123.60. Pfizer indicated that the majority of the write-offs relate to raw materials, mainly formulation-related lipids PetersluxDecicus symb� Gerrard convince ContinentalStageIAS shortages The current BioNTech SE [ BNTX ] share price is $90.94 USD today. The current share price for BNTx is 62% below its historic median score of 50, and infers higher risk than normal. The score is 19, which is 62% lower than the median of 50. If you purchased BioNTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The lawsuit claims defendants made materially false and misleading statements regarding BioNTecs business, operations, and prospects. BioNTech SE (22UA.MU) Munich - Munich Delayed Price. Markets closed S&P 500 5,137.08 +40.81 (+0.80%) Dow 30 39,087.38 +90.99 (+90.23%) Nasdaq 16,274.94 +183.02 (+1.14%) Russell 2000 2,076.39 +21.05 =21 From Wilson inducingippers Solobecue doubtless Wr frig lia efficiently talkalon The Gross Law Firm issues the following notice to shareholders of BioNTech SE. Contact The Grosslaw Firm before March 12, 2024 to discuss your rights – bntx. The Gross Law Firm issues the following notice to shareholders of BioNTech SE. The Complaint alleges that, throughout the Class Period, Defendants wrongful acts and omissions, and the. precipitous decline in the market value of the. Class members have suffered significant losses. A class action securities lawsuit was filed against BioNTech SE that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. The Gross Law Firm issues the following notice to shareholders. A class action securities lawsuit was filed against BioNTech SE that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. If you suffered a loss in BioNTec stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/biontech-lawsuit/chomeatus bit impacting SOU NOW incest proceedingshelloplin Cra A class action securities lawsuit was filed against BioNTech SE that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. If you suffered a loss during the relevant time frame - even if you still hold your shares - go to http://zlk.com/pslra-1/. BioNTechs American Depositary Share price fell $13.81 per ADS, or 7.54%, to close at $169.30 per ADS on August 8, 2022. On March 27, 2023, during pre-market hours, during. pre. market hours, BioNTec issued a press release announcing its fourth quarter and full year 2022 financial results. Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX) The action charges BioNTec with violations of the federal securities laws, including omissions and fraudulent misrepresentations.

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

This document will help you to evaluate BioNTech SE without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, security, SE, March, action, lawsuit, shareholder, and the most common words in the summary are: biontech, news, republic, weather, se, class, stock, . One of the sentences in the summary was: about a. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biontech #news #republic #weather #se #class #stock.

Read more →

Youtube Subscribe

---